The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever Registry by Ter Haar, NM et al.
  
The phenotype and genotype of mevalonate kinase deficiency: a 
series of 114 cases from the Eurofever Registry 
Running head: Phenotype and genotype of MKD 
Nienke M. ter Haar1* MD, Jerold Jeyaratnam2* BSc, Helen J. Lachmann3 MD PhD 
Anna Simon4 MD PhD Paul A. Brogan5 MD PhD, Matteo Doglio6 MD PhD, Marco 
Cattalini7 MD, Jordi Anton8 MD PhD, Consuelo Modesto9 MD Pierre Quartier10 MD, 
Esther Hoppenreijs11 MD, Silvana Martino12 MD PhD, Antonella Insalaco13 MD, 
Luca Cantarini14 MD PhD, Loredana Lepore15 MD,  Maria Alessio16 MD PhD, 
Inmaculada Calvo Penades17 MD PhD, Christina Boros18 MD PhD, Rita Consolini19 
MD PhD, Donato Rigante20 MD, Ricardo Russo21 MD, Jana Pachlopnik Schmid22  
MD PhD, Thirusha Lane3 RN MSc, Alberto Martini6,23 MD PhD, Nicolino Ruperto6 MD 
MPH, Joost Frenkel2* MD PhD, Marco Gattorno6* MD PhD; for the Paediatric 
Rheumatology International Trials Organisation (PRINTO) and Eurofever Project. 
 
1 University Medical Center Utrecht, Laboratory for Translational Immunology, 
Utrecht, The Netherlands 
2  University Medical Center Utrecht, Department of Pediatrics, Utrecht, The 
Netherlands 
3 University College Medical School, National Amyloidosis Center, Royal Free 
Campus, London, United Kingdom 
4
 Radboud University Medical Center, Nijmegen Center for Immunodeficiency and 
Autoinflammation (NCIA), Department of Internal Medicine, Nijmegen, Netherlands 
5 University College London Institute of Child Health, Infection, Inflammation, and 
Rheumatology Section; and Great Ormond Street Hospital NHS Foundation Trust, 
London, United Kingdom 
6 Istituto Giannina Gaslini, Pediatria II, Reumatologia, Genoa, Italy 
7 University of Brescia and Spedali Civili di Brescia, Pediatric Clinic, Brescia, Italy 
8 Hospital Sant Joan de Déu, University of Barcelona, Pediatric Rheumatology Unit, 
Esplugues (Barcelona), Spain 
9 Hospital Valle de Hebron, Reumatologia, Reumatologia Pediatrica, Barcelona, 
Spain 
10 Université Paris-Descartes, Hôpital Necker-Enfants Malades. Centre de référence 
national pour les Arthrites Juveniles, Unité d'Immunologie, Hématologie et 
Rheumatologie Pediatrique, APHP, IHU Imagine, Paris, France 
11Radboud University Medical Center, Nijmegen Center for Immunodeficiency and 
Autoinflammation (NCIA), Department of Pediatric Rheumatology, Nijmegen, 
Netherlands 
12Clinica Pediatrica Universita' di Torino, Dipartimento di Scienze Pediatriche e 
dell'Adolescenza, Day-Hospital Immuno-reumatologia, Torino, Italy 
13
 IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, 
Department of Pediatric Medicine, Rome, Italy 
14 University of Siena, Policlinico le Scotte, Rheumatology Unit, Siena, Italy 
15Universita' degli Studi di Trieste, IRCCS Burlo Garofolo, Scienze della Riproduzione 
e dello Sviluppo, Trieste, Italy 
Full Length Arthritis & Rheumatology
DOI 10.1002/art.39763
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/art.39763
© 2016 American College of Rheumatology
Received: Oct 25, 2015; Revised: Mar 08, 2016; Accepted: May 17, 2016
This article is protected by copyright. All rights reserved.
 2 
 
16Universita' di Napoli Federico II, Dipartimento di Pediatria, Napoli, Italy 
17University Hospital La Fe, Department of Pediatric Rheumatology, Valencia, Spain 
18Women's and Children’s Hospital, University of Adelaide, Discipline of Pediatrics, 
North Adelaide, SA, Australia 
19Ospedale Santa Chiara, Università di Pisa, Pediatria, Pisa, Italy  
20Università Cattolica Sacro Cuore, Institute of Pediatrics, Roma, Italy.  
21Hospital de Pediatria Juan P. Garrahan, Servicio de Inmunologia/Reumatologia, 
Buenos Aires, Argentina.  
22University Childrens Hospital Zurich, Division of Immunology, Zurich, Switzerland 
23Università degli Studi di Genova, Genoa, Italy 
 
* N.M. ter Haar and J. Jeyaratnam contributed equally to this study, J. Frenkel and M. 
Gattorno contributed equally as senior authors.  
 
Correspondence to: Joost Frenkel MD PhD, Department of General Pediatrics, 
University Medical Center Utrecht, Room KE 04 133 1, PO-Box 85090, 3508 AB 
Utrecht, The Netherlands. Phone number: 0031-88-7554194. Fax number: 0031-88-
7555349. E-mail: j.frenkel@umcutrecht.nl 
 
Financial support 
The Eurofever registry was sponsored by the Autoinflammatory Diseases’ Working 
Group of the Paediatric Rheumatology European Society (PRES) and supported by 
the Executive Agency For Health and Consumers (EAHC, Project No 
2007332) and by Coordination Theme 1 (Health) of the European Community's FP7 
(Eurotraps, grant agreement number HEALTH-F2-2008-200923). Novartis and SOBI 
have granted unrestricted educational grants.  
 
Conflict of interest  
The authors declare that they have no other competing interest. 
Acknowledgements  
The authors would like to thank Miss Eugenia Mosci, Irene Gregorini and Elisa 
Patrone for their precious secretarial support.  
 
Word count: 4272 
Abstract: 249 
 
 
 
 
 
 
Page 3 of 22
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
 3 
 
ABSTRACT 
Objectives: Mevalonate kinase deficiency (MKD) is a rare metabolic disease 
characterized by recurrent inflammatory episodes. This study aimed to describe the 
genotype, phenotype and the response to treatment in an international cohort of 
MKD patients. 
 
Methods: All MKD cases were extracted from the Eurofever registry (EAHC Project 
No. 2007332), an international, multicenter registry that retrospectively collects data 
on children and adults suffering from autoinflammatory diseases.  
 
Results: One hundred and fourteen MKD patients were included in this study. The 
median age of onset was 0.5 years. Patients had on average 12 episodes per year. 
Most patients had gastrointestinal symptoms (n=112), mucocutaneous involvement 
(n=99), lymphadenopathy (n=102) or musculoskeletal symptoms (n=89). 
Neurological complaints included headache (n=43), but also cerebellar syndrome 
(n=2) and mental retardation (n=4). AA-amyloidosis was noted in five patients, almost 
twice as many as expected from previous cohorts. Macrophage activation syndrome 
occurred in one patient. Between attacks patients were generally well, but 10-20% 
patients suffered from constitutional symptoms, such as fatigue, between febrile 
attacks. Patients with p.V377I/p.I268T compound heterozygosity suffered 
significantly more often from AA-amyloidosis. Patients without a p.V377I mutation 
suffered more often from severe musculoskeletal involvement. 
Treatment with NSAIDs could relieve symptoms. Steroids given during attacks, 
anakinra and etanercept appeared to improve symptoms and could induce complete 
remission in MKD patients.  
 
Conclusion: This study described the clinical and genetic characteristics of 114 MKD 
patients, which is the largest cohort studied so far. The clinical manifestations confirm 
earlier reports. However, the prevalence of AA-amyloidosis was far higher than 
expected.  
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INTRODUCTION 
Mevalonate kinase deficiency (MKD) is a rare autoinflammatory syndrome 
characterized by fever and generalized inflammation. The disease encompasses a 
continuum of two phenotypes, known as the Hyper Immunoglobulinemia D and 
periodic fever syndrome (HIDS, MIM#260920) and Mevalonic Aciduria (MA, 
MIM#610377) (1-4). Patients suffering from MKD present with fever, gastrointestinal 
complaints, lymphadenopathy, arthralgia, myalgia, skin rash and mucosal ulcers. 
Furthermore, patients suffering from the more severe phenotype Mevalonic Aciduria 
can also exhibit dysmorphic features, pre- and postnatal growth retardation and 
neurological and ocular involvement (5).  
Both phenotypes are caused by mutations in the mevalonate kinase (MVK) gene 
(6,7). This gene encodes mevalonate kinase, an enzyme that is part of the 
mevalonate pathway. This pathway produces cholesterol and unsaturated lipid 
chains, known as non-sterol isoprenoids (8). Activity of mevalonate kinase is reduced 
in MKD patients, varying from 1.8% to 28% in patients with the HIDS phenotype, to 
below 0.5% in patients affected by the MA phenotype, although overlap occurs 
(6,9,10). The substrate of this enzyme, mevalonic acid, accumulates and is excreted 
in the urine. Patients suffering from MKD therefore often excrete elevated amounts of 
mevalonic acid (10-14). Due to the lack of clinical criteria, patients can only be 
diagnosed by the identification of two pathogenic MVK mutations or by detection of 
decreased enzyme activity (15). 
The first MKD patients were described in 1984 (2). Currently, several hundred 
patients with this rare disease have been described. MKD has been more frequently 
reported in patients with Caucasian ethnicity; a disproportionate number of Dutch 
HIDS patients have been described, probably caused by a founder mutation 
(p.V377I) in this population (16). The current number of MKD patients is certainly an 
underestimate as many patients remain undiagnosed (8). As many physicians are 
still not familiar with this disease, the diagnostic delay is 7.1 years (17). MKD patients 
are often suspected of having other diseases, such as infections, immunodeficiency 
or other autoinflammatory syndromes before being diagnosed correctly (17). 
This study aimed to describe the clinical and genetic characteristics and the 
response to treatment in a large, international cohort, in order to increase knowledge 
about this rare disease and hence facilitate diagnosis and inform the discussion on 
treatment and prognosis with affected families. 
PATIENTS AND METHODS 
All patients were enrolled in the Eurofever registry (EAHC Project No. 2007332), an 
international, multicenter registry which retrospectively collects information on 
patients suffering from autoinflammatory diseases. Patients were enrolled since 
November 2009 (18). Epidemiological, demographic and clinical data were collected 
anonymously by local physicians. Independent ethical committee approval for 
enrolling patients was granted in accordance with local requirements. Written 
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informed consent was obtained from patients according to local ethical regulations. 
Two experts on MKD (AS and JF) checked the enrolled patient data on genetic, 
biochemical and clinical characteristics. For this analysis, all cases enrolled until 
November 2014 were included. Patients harboring two MVK mutations or harboring 
one mutation in combination with an abnormal metabolic study result were 
considered as true MKD patients. The metabolic studies utilized were either raised 
urinary mevalonic acid or reduced mevalonate kinase enzyme activity in leukocytes 
or fibroblasts.  
Response to different treatments (either on demand or continuous) was assessed as 
follows: complete response (complete control of the clinical manifestations and 
normalization of laboratory parameters), partial response (persistence of some 
clinical manifestations and/or perturbation of laboratory examinations) or failure 
(absence of any substantial impact on disease activity or worsening).  
Statistics  
All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) 21. Categorical variables were described as frequencies and percentages. 
Median and interquartile ranges (IQR) were used to describe numeric variables. To 
determine a genotype-phenotype relationship, differences in clinical features 
between groups with specific genotypes were analyzed using Fisher’s exact test. A 
p-value <0.05 was considered to be statistically significant. 
RESULTS 
Demographic data 
Up to November 2014, 161 patients had been enrolled by their local physicians in the 
Eurofever registry with a diagnosis of MKD. Nineteen of these patients were 
excluded because genetic testing had not been performed, no MVK mutations were 
found, or clinical data were incomplete. Another 28 patients with only one mutation 
were excluded as MKD could not be confirmed by demonstration of decreased 
mevalonate kinase activity or elevated urinary mevalonic acid excretion (figure 1). 
A total of 114 patients (53 male, 61 female) were entered by 31 centers from twelve 
countries. The majority of these patients was born in Italy (n=31) and the Netherlands 
(n = 28) (figure 2A). The median age of onset was 6 months (IQR 9 weeks to 19 
months) (figure 2B). The median age at diagnosis was 6.5 years (IQR 3.5-14.7 
years). Thus, the median diagnostic delay was six years (IQR 1.9-14.2 years) (figure 
2C). The median follow-up period since the age at onset was 11.5 years.  
Genetic characteristics  
Complete gene screening was performed in 47 (41%) patients, whereas in 46 (40%) 
patients only the most relevant exons were sequenced. In four (4%) patients only the 
most relevant point mutations were screened. Ninety-six patients harbored at least 
one p.V377I mutation (84%), fourteen of which were homozygous (12%). The second 
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most frequent mutation was p.I268T, occurring in 29 patients (25%). None of them 
were p.I268T homozygous (figure 2D). 
Two mutations were not present in the Infevers database (19). A p.C152Y mutation 
was found in one patient. This patient also had a p.V377I mutation and had a mild 
clinical pattern, as no musculoskeletal and neurological manifestations were 
reported. As this mutation was not known to be pathogenic, enzyme activity in both 
fibroblasts and leukocytes was performed, showing decreased activity in both 
assays.  
Further, a 447^448insGCCTAC mutation, which is not known to be pathogenic, was 
found in one patient who also had a p.V377I mutation. This patient was not severely 
affected, suffering mostly from gastrointestinal symptoms, myalgia and 
lymphadenopathy. Metabolic studies were not performed. 
Clinical characteristics 
Ninety-nine of 114 patients suffered from recurrent disease episodes, i.e. they 
recovered completely between attacks. Six patients suffered from continuous disease 
without clear-cut exacerbations, whereas nine patients had a continuous course with 
exacerbations. In these patients the intervals between attacks were characterized by 
some measure of ongoing inflammation. The median flare duration was four days 
and the median flare frequency was twelve episodes per year (figure 3A, 3B). Febrile 
episodes were provoked by specific triggers in 51 patients, mainly by vaccination 
(n=38), stress (n=26) and infection (n=18) (figure 3C).  
MKD symptoms and sequelae 
General features 
All clinical features are summarized in table 1. Detailed descriptions of patients with 
severe manifestations can be found in table 2. Seventy-nine patients had 
constitutional symptoms, such as malaise (n=70), fatigue (n=69) and weight loss 
(n=16). In 23% of these patients, malaise was reported independent of fever, while 
fatigue occurred independent of fever in 35% of them. Constitutional symptoms 
independent of fever were no predictor of a more severe course such as amyloidosis. 
Most patients (n=102) had lymphadenopathy, which was usually, but not exclusively 
cervical (n=96) and tender (n=59). Generalized lymphadenopathy occurred in a 
sizeable minority (n=39). 
Mucocutaneous involvement 
Ninety-nine patients suffered from mucocutaneous symptoms, such as aphthous 
stomatitis (n=67) and pharyngitis (n=31). Fifteen percent of patients had aphthous 
stomatitis independent of fever. Maculopapular rash (n=43) and urticarial-like rash 
(n=16) were seen between febrile episodes in 8% and 38%, respectively.  
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Musculoskeletal involvement 
Musculoskeletal symptoms were noted in 89 patients. Most had arthralgia (n=80) and 
myalgia (n=64), specifically during fever episodes (85% and 82%). Arthritis was less 
common (n=31) and resolved when the fever episode subsided in 91%. In total eight 
patients suffered from severe musculoskeletal involvement: flexion contractures 
(n=5), persistent arthritis (n=2), bone erosion (n=2), osteolytic lesions (n=2), osteitis 
(n=2), and bone deformity (n=1). These patients are described in more detail in the 
following paragraphs and table 2. 
One patient (pt 1) with persistent polyarthritis developed contractures and bone 
deformity. This patient also had severe gastrointestinal complaints, such as 
gastrointestinal bleeding and gastrointestinal and (peri)anal ulcers. The other patient 
with persistent arthritis did not have other severe manifestations.  
Two brothers, who had a compound heterozygous p.H20N and p.R215Q mutation, 
had flexion contractures, bone erosion and osteolytic lesions. The older brother (pt 2) 
had involvement of two joints and also had severe gastrointestinal involvement 
including aseptic peritonitis, gut perforation, intestinal occlusion and abdominal 
adhesions. Besides he suffered from scleritis. The younger brother (pt 3), who 
suffered from a continuous disease based on clinical features and chronic elevation 
of inflammatory parameters, had involvement of thirteen joints. Joint contractures 
appeared at the age of two years. 
Two patients suffered from osteitis. One of them (pt 4) had a continuous disease 
pattern and suffered from bacterial osteomyelitis. This patient also experienced 
aseptic peritonitis, intestinal occlusion and abdominal adhesions. The other patient 
(pt 5) suffered from osteitis without other severe manifestations. The osteitis was 
located in the right calcaneus. The blood culture was negative. One patient only had 
flexion contractures reported.  
Gastrointestinal involvement 
One-hundred and twelve patients had gastrointestinal (GI) complaints. Most of them 
experienced abdominal pain (n=98), diarrhoea (n=93) and vomiting (n=76). In more 
than 80% of patients, these symptoms were only seen during fever episodes. 
Eighteen patients had severe gastrointestinal symptoms: aseptic peritonitis (n=7), GI-
bleeding (n=7), (peri)anal ulcers (n=5), intestinal occlusion (n=3), gut perforation 
(n=2) and gastrointestinal ulcers (n=2).  
Abdominal adhesions were reported in four patients, although the modality of 
identification of this complication (imaging or after surgery) was not specified. Two 
sisters (pt 6 and 7) both had gastrointestinal bleeding. The elder sister also had 
uveitis and scleritis, while the younger sister had flexion contractures.  
Patient 8 suffered from aseptic peritonitis and (peri)anal ulcers. Another patient (pt 9) 
suffered from aseptic peritonitis and abdominal adhesions. One patient (pt 10), who 
had a continuous disease course, suffered from aseptic peritonitis, GI bleeding, gut 
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perforations and abdominal adhesions. This patient also experienced aseptic 
meningitis. She died due to acute respiratory distress syndrome before the age of 
one year. Ten additional patients had one severe GI manifestations namely GI 
bleeding (n=3), (peri)anal ulcers (n=3), aseptic peritonitis (n=2), intestinal occlusion 
(n=1) or GI ulcers (n=1), without other severe organ involvement. 
Neurological involvement 
Headache was the most common neurological complaint (n=43) and was reported 
independent of fever in 33% of the patients. Mood disorders were reported in 23 
patients. Moreover, 25% of these patients reported mood disorders between febrile 
episodes, thus reflecting the psychological impact of the disease, irrespectively from 
its recurrent or continuous course. Six patients had severe neurological 
manifestations, namely mental retardation (n=4), cerebellar syndrome (n=2) and 
aseptic meningitis (n=1). One patient (pt 11), who had a recurrent disease course, 
experienced both a cerebellar syndrome and mild mental retardation. This patient 
also had retinitis pigmentosa and has been described before as a case report (20). 
Another patient (pt 12) who had cerebellar disease, also suffered from a recurrent 
disease course. He was diagnosed with type 1 Arnold Chiari cerebellar syndrome as 
an incidental finding upon brain magnetic resonance imaging (MRI) performed at the 
age of two years. Despite this malformation, he showed normal psychomotor 
development. He had a twin who died in utero. One patient (pt 13) with mental 
retardation was heterozygous for p.I268T and p.P165L and had colitis as part of the 
MKD. The two other patients (pt 14 and 15) with mental retardation had no other 
severe manifestations.  
Macrophage activation syndrome 
Macrophage activation syndrome (MAS) arose in one patient (pt 16), who had a 
heterozygous p.V377I and del Exon 8 mutation. This patient has been described 
before (21). At the time, the patient only used flurbiprofen at full dosage and the 
disease was apparently well-controlled. The MAS presented initially as a typical MKD 
episode with high fever, arthralgia, myalgia and oral aphthae, which led to 
hospitalization. Two days after hospitalization, the patient was treated with several 
antibiotics due to presumed sepsis. The clinical picture worsened with initial heart 
failure and lethargy. Intensive care support with continuous ventilation was required. 
A bone marrow aspiration revealed activated macrophages and numerous 
hemophagocytic cells. The patient was treated with high dose methylprednisolone 
(30mg/kg/day) for four days. Hereafter, maintenance steroid therapy (1mg/kg/day) 
and ciclosporin (4mg/kg/day) were given.  
AA-amyloidosis 
AA-amyloidosis was diagnosed in five patients. The median diagnostic delay to the 
diagnosis of MKD in these five patients was 23 years (range 15 - 41 years). The 
median disease duration before the diagnosis of amyloidosis was 23 years (range 8 - 
37 years). 
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One of these five patients (pt 17) had a p.V377I mutation in combination with a 
p.L234P mutation. He presented with end stage renal failure at the age of 39 years 
and also had involvement of the liver and spleen. A renal transplantation was 
performed two years after the diagnosis of amyloidosis with good graft function.  
The other four patients (pt 18-21) were compound heterozygous for the p.V377I 
mutation and the p.I268T mutation. In one of these four patients (pt 18), AA-
amyloidosis presented with end stage renal failure at the age of 27 years and was 
diagnosed by biopsy, showing involvement of the kidneys and spleen. She suffered 
from persistent inflammation with continuously elevated inflammatory parameters. 
She died at the age of 45 due to complications after eighteen years of dialysis.  
Patient 19 presented with end stage renal failure at the age of 19 years. Serum 
Amyloid P (SAP) component scintigraphy showed involvement of kidneys, spleen 
and liver. He underwent a live-related renal transplant twice. The first kidney was lost 
due to recurrent amyloid deposition. The second transplantation led to good graft 
function. After the first renal transplantation the disease was not well controlled with 
anakinra and subsequently etanercept. During a period of five years the patient did 
not use any biological. Four months before the second transplantation treatment with 
tocilizumab was started with complete response. In his brother (pt 20) amyloidosis 
was diagnosed at the age of 37 years after presentation with end stage renal failure. 
SAP scintigraphy showed involvement of the kidneys, spleen and liver. He underwent 
a live-related renal transplant a year after diagnosis with good result.  
The last patient (pt 21) was diagnosed with amyloidosis at the age of eight years. 
Treatment with colchicine was started due to suspected FMF. At the age of twelve 
years she underwent kidney transplantation. When she was eighteen years old, she 
was diagnosed diagnosed as having MKD. She died at the age of nineteen years. 
Laboratory findings 
Abnormal immunoglobulin (Ig)D levels were found in 55 of 76 tested patients. Other 
immunoglobulin levels were also measured: IgA was elevated in 48 of 90 patients, 
while IgG was elevated in fourteen of 91 tested patients. IgM was within normal 
range in 81 of the 91 tested patients.  
Measurement of urinary mevalonic acid was performed in 40 patients; 37 of them 
showed elevated excretion. Thus, three patients excreted normal amounts of 
mevalonic acid. All three of them suffered from typical MKD symptoms. The first 
patient was homozygous for p.V377I and had a confirmed impairment of mevalonate 
kinase enzyme activity. Urine was collected during a febrile episode. This patient has 
been described before in a diagnostic study (22). The second patient was compound 
heterozygous for p.R388X and stop397R. In this patient mevalonic acid was 
measured as part of the whole organic acid screening. It is unknown whether this 
patient was well or febrile during urine sampling. The last patient was compound 
heterozygous for p.V377I and p.V310M and had a mild clinical pattern. In this patient 
urine was not collected whilst febrile.  
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Enzymatic studies in both leukocytes and fibroblasts were performed in 19 patients. 
Reduced mevalonate kinase enzyme activity in fibroblasts was found in seven of 
eight tested patients, while fifteen of sixteen tested patients showed reduced enzyme 
activity in leukocytes. Unexpectedly, one patient with a homozygous p.V377I 
mutation, typical MKD symptoms and elevated urinary mevalonic acid excretion 
exhibited normal enzyme activity in both fibroblasts and leukocytes. 
Associations between the genotype and phenotype 
To analyze genotype-phenotype associations, we divided all patients into four 
groups: homozygous p.V377I; compound heterozygous p.V377I and p.I268T; 
patients with one p.V377I mutation and a second mutation other than p.V377I or 
p.I268T; and patients without a p.V377I mutation. The frequency of MKD features 
was compared between the groups. Four out of 25 patients with p.V377I/p.I268T 
combined heterozygosity experienced amyloidosis as compared to one out of 89 
patients with other genotypes (p=0.049). Further, patients with mutations other than 
p.V377I mutation suffered more often from a continuous course, musculoskeletal, 
severe musculoskeletal involvement and severe gastrointestinal involvement (table 
3). 
Treatment 
NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) were used in 66 patients, usually to 
treat the symptoms of attacks, and were beneficial in 48 of them. Seven of these 
patients reported a complete response to NSAIDs. Five of them used NSAIDs during 
attacks only and not as maintenance therapy. Two of them used NSAIDs as 
monotherapy, the other five in combination with corticosteroids. The response to 
steroids was reported as complete in four of them and as partial in one.   
Corticosteroids 
Corticosteroids were used by 49 patients to treat fever attacks. Nineteen of them 
reported complete suppression of inflammatory episodes (16/19 had not used 
biologics) and 21 patients reported some improvement. Five out of seven patients 
who used maintenance corticosteroids reported some benefit, failure was noted in 
the other two. 
Colchicine and statins 
Colchicine was used by 21 patients; thirteen of them did not respond to this treatment 
and only one patient with p.V377I/p.S135L heterozygosity had a complete response. 
Mediterranean Fever (MEFV) screening had not been performed in this Caucasian 
patient from Italy. This patient did not use NSAIDs, steroids or biologics. Statins were 
used in fifteen patients; in eleven patients this treatment failed, moreover three of 
them reported worsening of their disease. Four patients noted some improvement of 
symptoms. 
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Biologicals 
Anakinra was used only during attacks in eight patients, with three of them having a 
complete response and the other five a partial response. Nineteen patients used 
anakinra as maintenance therapy, which led to complete remission in three of them 
and a partial response in thirteen. In three patients anakinra was not effective. All 
three suffered from a recurrent disease pattern. One of them was severely affected 
and suffered from cerebellar syndrome, mental retardation and retinitis pigmentosa. 
The two other patients were mildly affected and did not have severe manifestations. 
In at least seven patients with an initial failure or partial response on anakinra the 
dose of anakinra was raised. This did not lead to complete remission. Four of these 
seven patients have switched to another therapy, three of them are still using 
anakinra. In another six patients with an initial partial response, the dose was not 
raised. Though, three of them are still using anakinra.  
Five patients were treated with canakinumab; four of whom achieved complete 
remission, while one had a partial response. The patient with a partial response was 
a p.V377I/p.G338D compound heterozygote and had failed on NSAIDs, steroids, 
anakinra, etanercept and adalimumab, before the initiation of canakinumab. Two 
patients with a complete response had a partial response on anakinra before 
treatment with canakinumab.  
Etanercept was prescribed to 27 patients: it had a beneficial effect in sixteen patients, 
of whom two had a complete response. Eleven patients failed to respond to 
etanercept.  
DISCUSSION 
This study describes the phenotypic and genotypic characteristics and the response 
to treatment in the largest cohort of MKD patients reported so far. Moreover, the vast 
majority (87) of these patients has not been described in previous cohorts (10,23). 
This large cohort enables us to give a broad description of the clinical features and 
treatment of this rare disease.  
 
In many respects, our study confirms the clinical characteristics reported by previous 
studies. Typically, the disease starts within the first year of life. Onset after the age of 
4 years makes the diagnosis extremely unlikely. The most common symptoms were 
fever, abdominal pain, diarrhoea, vomiting, lymphadenopathy, arthralgia, myalgia and 
aphthous stomatitis. Five patients suffered from AA-amyloidosis, a frequency almost 
twice of that reported in previous cohorts (23). This might be due to reporting bias, 
since these patients are more likely to be enrolled in the registry. Still, this number 
might be an under-representation due to the limited follow-up: the median age of 
enrolled patients was only 12 years, while amyloidosis occurred after 18 years in 4/5 
patients Only one patient in our cohort experienced a macrophage activation 
syndrome, which is less than described in the study of Bader-Meunier et al (10). 
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Many patients had complaints between attacks. This concerned mainly constitutional 
symptoms such as fatigue, malaise and headache, but also oral aphthous ulcers. It 
has to be noted that these are also very common symptoms in the general population 
and has been found in increased numbers in rheumatic diseases (24,25). In our 
cohort patients with constitutional symptoms between attacks did not have a more 
severe course such as amyloidosis.  
According to the enrolling centers, up to 25% of the patients displayed some mood 
disorders. In the original survey the definition of mood disorders was left to the 
discretion of the enrolling physicians. However, this relatively high frequency possibly 
reflects the psychological impact of the disease, as already reported by van der Hilst 
et al (23).  
Although uncommon, some patients in our series did have severe musculoskeletal 
manifestations, such as persistent arthritis. In these severe cases, the differentiation 
between MKD and other pediatric rheumatic diseases such as systemic juvenile 
idiopathic arthritis (sJIA) can be hard. However, the disease course with frequent, 
short fever attacks alternating with prolonged episodes of spontaneous remission 
renders diagnoses like sJIA highly unlikely. 
This study confirms previous findings that measurement of IgD is not a reliable 
method to diagnose MKD, as 28% of the tested patients in this cohort did not have 
elevated IgD levels (15). Further, measurement of urinary mevalonic acid is a 
sensitive method for screening on MKD, as 93% of the tested patients excreted 
elevated amounts of mevalonic acid (10,22). The failure to detect mevalonic acid in 
some may be due to methodological limitations, as isotope dilution had not been 
employed in all of these patients. Unexpectedly in one patient, measurement of 
mevalonate kinase enzyme activity was reportedly entirely normal in the presence of 
known pathogenic mutations and elevated urinary excretion of mevalonic acid. 
Enzymatic studies have been regarded as the diagnostic gold standard for 
mevalonate kinase deficiency (8). However, apparently even enzyme activity assays 
may yield false negative results. 
 
The most frequent combination of mutations was p.V377I/I268T heterozygosity 
occurring in 22% of the patients, followed by p.V377I homozygosity in 12%. Patients 
with a combined heterozygosity for p.V377I/p.I268T suffered significantly more often 
from AA-amyloidosis.  
 
As reported previously, treatment with statins and colchicine was not effective in 
most patients (23,26). Seventy-five percent of the patients reported at least some 
benefit when using NSAIDs, but efficacy was rarely complete. Corticosteroids are 
more effective to terminate inflammatory attacks, but long-term side effects are a 
major drawback. Interleukin (IL)-1 blockade is beneficial in many MKD patients, but 
apparently not as effective as observed in the IL-1 driven cryopyrin-associated 
periodic syndromes  (26). Although the number of MKD patients reported here is 
substantially larger than that described in a previous paper on therapy in the 
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Eurofever cohort, the findings on therapy remain essentially unchanged (26). Some 
patients did not benefit from the use of biologicals. From the available data it cannot 
be excluded that these patients received an insufficient dose. However, from seven 
known patients, dose increase of anakinra did not result in complete control of the 
symptoms. 
 
The retrospective design of the Eurofever registry comes with a number of 
limitations. Due to this design, there were a number of variables reported as “not 
known” by the centers. This was mainly due to the fact that some variables requested 
by the Eurofever registry could not be retrieved from the clinical chart, because they 
were not investigated at the moment of the patients’ evaluation. This issue might 
have induced a bias, with a possible under-representation of some symptoms. For 
that reason, we have chosen to use the number of known values as denominator in 
the tables. Further, the Eurofever Registry collects data on patients suffering from 
periodic fever. The participating physicians are (pediatric) immunologists and 
(pediatric) rheumatologists. As Mevalonic Aciduria patients experience predominantly 
neurological symptoms, these patients are more likely to be seen by a (pediatric) 
neurologist or a specialist in metabolic diseases. Therefore, some of the more 
severely affected MKD patients may not have been enrolled. Besides, Mevalonic 
Aciduria patients may be under-represented as they are more likely to die at a young 
age (27). Still, our cohort included some patients who can be classified as MA. Also, 
many patients were enrolled by European centers as the Eurofever registry is 
predominantly known in Europe. Finally, the involvement of more pediatric than adult 
specialists may have introduced an age bias. MKD does not seem to carry a high 
mortality rate, yet the median age of enrolment in our cohort was 12 years. A long 
follow-up is needed to acquire information about long term complications. A limitation 
to the interpretation of therapeutic interventions is the absence of clear criteria for 
complete and partial response. The response was left to the interpretation of the 
physician. Bias is inevitable due to the lack of control groups and randomization. 
Furthermore, as it is unknown whether drugs were used simultaneously or 
sequentially, it is even more difficult to draw solid conclusions about the efficacy of 
treatments. However, the Eurofever registry does provide information on current 
practice.  
 
In conclusion, we have described the clinical and genetic features in the largest, 
international cohort of MKD patients. Most MKD patients suffered from fever, 
accompanied by gastrointestinal symptoms, lymphadenopathy, arthralgia and 
aphthous stomatitis. AA-amyloidosis (4%) and macrophage activation syndrome 
(0.9%) were rare, but severe complications of MKD. Patients could benefit from 
treatment with NSAIDs, steroids and biologics, mainly IL-1 blockers and etanercept. 
Statins and colchicine were usually not effective in MKD patients.  
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Table 1. Clinical characteristics of 114 MKD patients 
 
      n   % during+ % also  
every episode present 
between 
episodes++ 
Disease pattern 
   Recurrent     99   (87%)  
   Continuous with exacerbations  9   (8%) 
   Continuous     6   (5%) 
Constitutional symptoms*   79/111   (71%)  
   Malaise     70/108   (65%) 53%  23% 
   Fatigue     69/109   (63%) 52%  35% 
   Weight loss     16/102   (16%) 
Lymphoid organs    102/113 (90%) 
   Generalized enlargement   39/103   (38%) 36%  22% 
   Cervical lymphadenopathy   96/113   (85%) 64%  15% 
   Painful lymph nodes    59/99   (60%) 42%  12%  
Mucocutaneous involvement   99/113   (87%) 
   Aphthous stomatitis    67/111   (60%) 37%  15% 
   Maculopapular rash   43/111   (39%) 21%  8% 
   Urticarial rash    16/109   (15%) 38%  38% 
   Exudative pharyngitis   31/109   (28%) 16%  10% 
Musculoskeletal involvement   89/113   (79%) 
   Arthralgia     80/113   (71%) 34%  15% 
   Myalgia     64/112   (57%) 34%  18% 
   Arthritis     31/109   (28%) 24%  9% 
   Severe musculoskeletal involvement** 8/110    (7%) 
Gastrointestinal symptoms   112/114 (98%) 
   Abdominal pain    98/111   (88%) 44%  16% 
   Diarrhoea     93/111   (84%) 38%  11% 
   Vomiting     76/110   (69%) 29%  18% 
   Severe gastrointestinal involvement*** 18/114  (16%) 
Ocular involvement    17/113   (15%) 
   Conjunctivitis    11/113   (10%) 9%  36% 
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   Uveitis     2/113   (2%) 
   Impaired vision     2/113   (2%) 
   Cataract     3/113   (3%) 
Neurological involvement   46/114   (41%) 
   Headache      43/114   (38%) 40%  33% 
   Mood disorders    23/95     (24%)  43%  25% 
   Severe neurological involvement**** 6/114   (5%) 
 
The denominator varies as missing values are disregarded in this table. The percentage is taken from 
the number of known values.  
*Constitutional symptoms were defined as fever, malaise, fatigue, mood disorders or weight loss.  
**Severe musculoskeletal involvement was defined as flexion contractures, bone deformity, bone 
erosion, persistent arthritis, osteitis or osteolytic lesion.  
***Severe gastrointestinal involvement was defined as aseptic peritonitis, gastrointestinal bleeding, 
intestinal occlusion, gut perforation, abdominal adhesions, gastrointestinal ulcers and (peri)anal ulcers. 
****Severe neurological involvement was defined as cerebellar syndrome, mental retardation or 
aseptic meningitis.  
+
During every episode means that the symptom was present during every febrile episode. 
++
Also present between episodes means that the symptom was not only present during fever 
episodes, but also in between.  
 
Table 2. Severely affected patients 
Pt Severe 
manifestations 
Mut 1 Mut 2 Age at 
onset 
(years) 
Diagnost
ic delay 
(years) 
Episode 
duratio
n (days) 
Disease 
course 
Treatment with 
biologicals 
1 MSK, GI  p.H20Q p.H20Q 0.2 0.2 4 REC etanercept PR  
2 MSK, GI, EYE p.H20N p.R215Q 0.1 14.8 5 REC anakinra 
maintenance CR, 
etanercept PR 
3 MSK p.H20N p.R215Q 0 4.5 x CNT anakinra PR, 
etanercept fail 
4 MSK, GI p.P165L p.I268T 0 1.5 x CNT anakinra 
maintenance PR,  
etanercept fail 
5 MSK p.V377I p.S329R 7.8 0 4 REC canakinumab CR, 
etanercept PR 
6 GI, EYE p.V310L p.V310L 3.3 23.1 x CNT  
7 MSK, GI  p.V310L p.V310L 3 14.2 x CNT anakinra 
maintenance PR 
8 GI p.G336S p.N166I 4.9 36.1 7 REC  
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9 GI p.V377I p.I268T 0.1 26.9 4 REC anakinra during 
attacks PR, 
etanercept PR 
10 GI, NEU p.T237S p.I268T 0.01 0.7 x CNT  
11 NEU, EYE p.A334T p.A141fs  0.01 2.1 4 REC anakinra 
maintenance fail 
12 NEU p.V377I  p.V377I  0.5 5.5 4 REC  
13 NEU p.P165L p.I268T 0.3 5.4 no 
specific 
pattern 
REC anakinra during 
attacks PR 
14 NEU p.V377I  c.606insG 0.3 1.2 3 REC  
15 NEU p.V377I p.I268T 0.6 1.1 5 REC  
16 MAS,  EYE p.V377I del exon 
8 
2 4.3 5 REC anakinra PR, 
canakinumab CR 
17 amyloidosis p.V377I p.L234P 2.1 41.1 6 REC anakinra during 
attacks PR, 
etanercept PR, 
tocilizumab PR 
18 amyloidosis p.V377I p.I268T 4 23.7 not 
known 
REC  
19 amyloidosis p.V377I p.I268T 4 14.8 10 REC anakinra 
maintenance PR, 
etanercept fail, 
tocilizumab CR 
20 
 
 
amyloidosis p.V377I p.I268T 3 24.5 13 REC anakinra 
maintenance PR 
 
 
21 amyloidosis p.V377I p.I268T 0.1  17.7 x CNT  
         
Severe manifestations: GI: gastrointestinal, NEU: neurological, MSK: musculoskeletal, EYE: ocular. 
Disease course: CNT: continuous, REC: recurrent. Therapy: CR: complete response, PR: partial 
response.  
Table 3. Associations between the genotype and clinical characteristics 
 
 
Genotype/  p.V377I+ p.V377I+ p.V377I+ patients without p-value 
phenotype  p.V377I (n=14) p.I268T (n=25) other (n=57) p.V377I (n=18) 
 
Continuous course 0%  4%  0%  28%  0.000 
Family history  45%  38%  29%  53%  ns 
Constitutional   85%  68%  85%  89%  ns 
symptoms   
 
Mucocutaneous 100%   76%  91%  78%  ns 
involvement   
 
Gastrointestinal  100%  96%  100%  94%  ns 
involvement   
 
Severe gastrointestinal 0%  16%  12%  39%  0.02 
involvement  
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Lymphoid  93%  92%  89%  89%  ns 
involvement  
  
Ocular    21%  8%  11%  35%  ns 
involvement   
 
Neurological   64%  48%  30%  47%  ns 
involvement   
 
Severe neurological 14%  4%  2%  20%   ns 
involvement 
 
Musculoskeletal  86%  64%  77%   100%  0.025 
involvement  
     
Severe musculoskeletal 0%  0%  4%  50%  0.001 
Involvement 
 
Amyloidosis  0%  16%  2%  0%  0.049 
Patients were compared with patients from the other groups regarding the clinical variables, using 
Fisher exact test. A p-value <0.05 was considered to be significant.  
 
 
Figure 1. Flowchart of included patients 
 
Figure 2. Characteristics of 114 MKD patients 
 
A. Country of birth of 114 MKD patients. The numbers in brackets indicate the number of patients. Other countries 
included Albania, Australia, Cyprus, Czech Republic, Morocco, Russia and Turkey. B. Age at onset of 114 MKD 
patients. The numbers in brackets indicate the number of patients. C. Diagnostic delay according to the year of 
birth from patients born since 1980. D. The genotype of all patients. The numbers in brackets indicate the number 
of patients. 
 
Figure 3. Features of inflammatory attacks in 108 MKD patients. 
 
A. Episode duration in days. B. Frequency of the number of episodes per year. C. Episode triggers in 51 MKD 
patients. Other triggers include cold (n=4); exercise (n=5); trauma (n=2); food (n=1); menstruation (n=4); fatigue 
(n=6); travel (n=1). 
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Figure 1. Flowchart of included patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           161 patients 
 
142 patients 
 
 
11- no MVK analysis performed 
7- no MVK mutations found 
1- incomplete clinical data 
28 patients with 1 mutation 
excluded as metabolic studies did 
not confirm MKD 
  
               114 patients 
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A. Country of birth of 114 MKD patients. The numbers in brackets indicate the number of patients. Other 
countries included Albania, Australia, Cyprus, Czech Republic, Morocco, Russia and Turkey. B. Age at onset 
of 114 MKD patients. The numbers in brackets indicate the number of patients. C. Diagnostic delay 
according to the year of birth from patients born since 1980. D. The genotype of all patients. The numbers 
in brackets indicate the number of patients.  
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A. Episode duration in days. B. Frequency of the number of episodes per year. C. Episode triggers in 51 MKD 
patients. Other triggers include cold (n=4); exercise (n=5); trauma (n=2); food (n=1); menstruation 
(n=4); fatigue (n=6); travel (n=1).  
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